Planejamento, síntese e avaliação farmacológica de novos protótipos de fármacos vasorelaxantes
Carregando...
Data
2012-08-24
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Goiás
Resumo
Cardiovascular diseases are the leading cause of death worldwide, so the search for
cardiotonic drugs more effective, safer and with lower side effects compared to currently
available therapy, is of fundamental importance.
Thus, we used in our design the phosphodiesterase 3 inhibitors, milrinone (13) and
cilostazol (4), which show positive inotropic activity, relaxation effect and vasodilators. The
new heterocyclic compounds (20a-20o) were originally designed by applying molecular
hybridization strategy from these lead-compounds.
The synthetic route to obtain the compounds 20a-20o resulted in overall yields ranging
from 16.2 and 73.4%. During the synthesis, we used the Duff reaction conditions to
formylation of N-phenylpyrazoles (1-phenyl-1H-pyrazole) (9a-o), which was an alternative
synthetic methodology to classic Vilsmeier-Haack conditions. All the synthesized compounds were characterized by infrared and NMR spectroscopy combining the 1H, 13C, HSQC and HMBC correlation spectra. The compounds 20c, 20d, 20e, 20f and 20g, were evaluated for their relaxation profile of vascular smooth muscle. From this preliminary test, the 20d compound was selected to be
further evaluated in pharmacological models, as provided better relaxation among this series of compounds in order to investigate the action mechanism. In these assays, 20d compound showed a relaxing activity in isolated arteries, potentiate by the presence of endothelium, with the participation of routes GCs/GMPc and AC/AMPc and where the flows of K+ and Ca2+through the membrane and the uptake of Ca2+ by the sarcoplasmic reticulum are important. Given the promising pharmacological profile of 20d compound, it was subjected to safety testing in preclinical in vitro model of the neutral red incorporation by cultures of 3T3 cells and acute oral toxicity tests. According to the International Organization for Economic
Cooperation and Development (OECD) 423, the 20d compound was classified in 4 class,
which shows that the compound was tolerated at a dose of 2000mg/kg orally.
At the end of this work, we conclude that the design strategy employed has been
validated, as the 20d compound showed a similar pharmacological profile to lead-compounds milrinone (13) and cilostazol (4). The pharmacological evaluation of all synthesized compounds in this work, will serve as a guide to establish the structure activity relationship of the series, and in turn, lead future changes on the chemical structures of the compounds for the activity cardiotonic optimization.
Descrição
Palavras-chave
Citação
PAZINI, Francine. Planejamento, síntese e avaliação farmacológica de novos protótipos de fármacos vasorelaxantes. 2012. 505 f. Tese (Doutorado em Química) - Universidade Federal de Goiás, Goiânia, 2012.